Results 51 to 60 of about 2,780 (190)

Increase in CIP2A expression is associated with doxorubicin resistance [PDF]

FEBS Letters, 2011
The cancerous inhibitor of protein phosphatase 2A (CIP2A) increases the migration and metastasis of various cancer cells. Overexpression of CIP2A has been shown to increase the proliferation of MDA-MB-231 cells. We thus assessed whether CIP2A expression is associated with sensitivity to doxorubicin.
Choi, Yeon A., Park, Jeong Su, Park, Mi Young, Oh, Ki Sook, Lee, Myung Sok, Lim, Jong-Seok, Kim, Keun Il, Kim, Kun-yong, Kwon, Junhye, Yoon, Do Young, Moon, Eun-Yi, Yang, Young   +11 more
openaire   +2 more sources

Assessment of CIP2A and ROCK-I expression and their prognostic value in breast cancer

Polish Journal of Pathology, 2020
Breast cancer is the most leading cause of cancer death in females worldwide. Identification of novel biomarkers for prognosis is required. Imunohistochemical evaluation of CIP2A and ROCK-1 expressions in 126 breast tissue specimens stratified as 21 ...
Nisreen Tawab Osman, Manal Khalaf, Shaymaa Ibraheem   +2 more
doaj   +1 more source

EPMA position paper in cancer:current overview and future perspectives [PDF]

, 2015
At present, a radical shift in cancer treatment is occurring in terms of predictive, preventive, and personalized medicine (PPPM). Individual patients will participate in more aspects of their healthcare.
Bubnov, Rostylav, Danesi, Romano, Desiderio, Dominic M., Grech, Godfrey, Hagan, Suzanne, Vittadini, Giorgio, Yoo, Byong Chul, Zhan, Xianquan   +7 more
core   +5 more sources

CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis [PDF]

, 2021
Basal-like breast cancers (BLBC) are characterized by defects in homologous recombination (HR), deficient mitotic checkpoint, and high-proliferation activity. Here, we discover CIP2A as a candidate driver of BLBC.
Butt, Umar, Connolly, Denise C., Cvrljevic, Anna N., de Visser, Karin, Elo, Laura L., Farrington, Caroline, Feringa, Femke M., Gautam, Prson, Gronroos, Tove J., Joensuu, Heikki, Khan, Sofia, Kronqvist, Pauliina, Laine, Anni, Maurer, Jochen, Medema, Rene H., Nagelli, Srikar G., Narla, Goutham, Pavic, Karolina, Peuhu, Emilia, Qiao, Xi, Sihto, Harri, Vainonen, Julia P., Wennerberg, Krister, Westermarck, Jukka   +23 more
core   +1 more source

Prognostic value of the NLR combined with CIP2A in the serum of patients with colorectal cancer

BMC Surgery, 2021
Objective This study aimed to investigate the prognostic value of CIP2A (cancerous inhibitor of protein phosphatase 2A) and the NLR (neutrophil–lymphocyte ratio) in the serum of patients with CRC (colorectal cancer) after resection.
Wei Chen, Hong-Jun Yi, Xiao-Qiong Chen, Wan-Zhen Xie, Xing-kui Tang, Jun-Wen Ye, Xiang Peng, Yan Zhang, Jing-Lin Liang, Mei-Jin Huang   +9 more
doaj   +1 more source

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire [PDF]

, 2012
Idiosyncratic adverse drug reactions are unpredictable, dose independent and potentially life threatening; this makes them a major factor contributing to the cost and uncertainty of drug development. Clinical data suggest that many such reactions involve
A. Lucas, A. M. English, A. Sette, A. Wriston, B. J. Grant, B. Peters, C. A. F. de Oliveira, C. Oseroff, Cahalan, Chessman, Chung, D. A. Ostrov, D. F. Hunt, Day, E. Phillips, Faletto, Friesner, H. M. Grey, H. Mei, Harndahl, J. Jakoncic, J. Shabanowitz, J. Sidney, Ko, L. Shi, L. Yang, Lavergne, M. Harndahl, Mallal, Martin, Melroy, Phillips, Pichler, Rudolph, S. Buus, S. Lu, S. Mallal, S. Southwood, Shastri, Shimizu, Sidney, Sidney, Tenzer, Udeshi, Y. A. Pompeu, Yang, Yang, Yewdell   +47 more
core   +4 more sources

Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer

Cell Communication and Signaling, 2020
Background Increasing evidence has revealed a close correlation between cancerous inhibitor of protein phosphatase 2A (CIP2A) and cancer progression. CIP2A has been shown to participate in diverse biological processes, such as development, tumorigenic ...
Wei Chen, Jing-Lin Liang, Kai Zhou, Qing-Li Zeng, Jun-Wen Ye, Mei-Jin Huang   +5 more
doaj   +1 more source

CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease

Cell Reports, 2018
Summary: Protein phosphatase 2A (PP2A) inhibition causes hyperphosphorylation of tau and APP in Alzheimer’s disease (AD). However, the mechanisms underlying the downregulation of PP2A activity in AD brain remain unclear.
Yang-Ping Shentu, Yuda Huo, Xiao-Long Feng, James Gilbert, Qing Zhang, Zhen-Yu Liuyang, Xiu-Lian Wang, Guan Wang, Huan Zhou, Xiao-Chuan Wang, Jian-Zhi Wang, You-Ming Lu, Jukka Westermarck, Heng-Ye Man, Rong Liu   +14 more
doaj   +1 more source

Prognostic significance of CIP2A expression in solid tumors: A meta-analysis. [PDF]

PLoS ONE, 2018
CIP2A, cancerous inhibitor of protein phosphatase 2A, was initially recognized as an oncoprotein. Recently several studies revealed that CIP2A could function as a prognosis biomarker, however, the result remained not comprehensive, partly due to small ...
Min Tang, Jiao-Feng Shen, Ping Li, Li-Na Zhou, Ping Zeng, Xi-Xi Cui, Min-Bin Chen, Ye Tian   +7 more
doaj   +1 more source

Expression and biological role of CIP2A in human astrocytoma

Molecular Medicine Reports, 2013
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently characterized oncoprotein involved in the progression of several human malignancies. The present study aimed to investigate the clinical significance and biological function of CIP2A in astrocytoma.
Fuxin, Yi, Weimin, Ni, Weixian, Liu, Jinyang, Bai, Wenbin, Li   +4 more
openaire   +3 more sources